Aims Meltdose tacrolimus (Envarsus) is marketed as a formulation with a more consistent
exposure. Due to the narrow therapeutic window, therapeutic drug monitoring is essential to …

The highly variable pharmacokinetics and narrow therapeutic window of tacrolimus (TAC)
has hampered its clinical use. Genetic polymorphisms may contribute to the variable …

Abstract Background Cytochrome P450 (CYP) 3A polymorphisms are associated with
variable CYP 3A metabolizing enzyme activity and tacrolimus pharmacokinetics. We sought …

Background: Intrapatient variability (IPV) in tacrolimus exposure is associated with renal
allograft failure. The aim of this study was to investigate whether conversion from the twice …

Lung transplant patients present important variability in immunosuppressant blood
concentrations during the first months after transplantation. Pharmacogenetics could explain …

Abstract Purpose Machine Learning (ML) algorithms represent an interesting alternative to
maximum a posteriori Bayesian estimators (MAP-BE) for tacrolimus AUC estimation, but it is …

Aim: To test the relevance of revisiting the genotype classification based on CYP3A5* 3
solely by incorporating CYP3A4* 22 information. Methods: Discriminant analysis of principal …

Renal transplantation represents the most favorable treatment for patients with advanced
renal failure and it is followed, in most cases, by a significant enhancement in patients' …

Purpose The objective of this study was to merge genetic and non-genetic factors of
tacrolimus pharmacokinetics to establish a more stable population pharmacokinetic model …

Cyclosporine (CsA) and tacrolimus (TAC) are immunosuppressant drugs characterized by a
narrow therapeutic range and high pharmacokinetic variability. The effect of polymorphisms …